Approval basis: The FDA determined the generic is therapeutically equivalent to Climara Pro. Generic approval relies on pharmaceutical equivalence and bioequivalence; no new comparative efficacy trial results were reported.
Approved uses: For women with an intact uterus who require hormone therapy for moderate to severe menopausal vasomotor symptoms or prevention of postmenopausal osteoporosis.
Key Findings:
The combination patch contains estrogen and progestogen; levonorgestrel is included to reduce the risk of endometrial hyperplasia associated with unopposed estrogen exposure.
Contraindications include certain cancers, undiagnosed abnormal genital bleeding, thromboembolic disease, hepatic disease, hypersensitivity, and certain thrombophilic disorders.
Adverse reactions reported in at least 5% of patients include application-site reactions, vaginal bleeding, breast pain, upper respiratory tract infections, back pain, depression, pain, headache, and flu syndrome.
The therapy carries established risks associated with systemic estrogen-progestogen treatment, including cardiovascular and thromboembolic events and certain malignancies.
Interpretation:
The approval provides a generic alternative to an existing branded treatment; it does not add a new active ingredient, indication, or route of administration.
Limitations:
The FDA announcement reported no new comparative efficacy trial results.
Commercial availability and pricing were not announced.
Conclusion:
The FDA advised contacting Zydus Pharmaceuticals for availability information.
